Redwood City, California – February 20, 2018 – Synthego, a leading provider of genome engineering solutions, today announced it has been named one of the Top 10 Most Innovative Companies in Biotech for 2018 by Fast Company. Each year, Fast Company publishes rankings of the world’s most innovative companies, honoring leading enterprises and rising newcomers that exemplify the best in business and innovation.
Genome engineering using CRISPR technology allows scientists to precisely and efficiently edit DNA to cure disease and solve humanity’s biggest challenges, making it the most exciting life sciences advancement in the past several decades.
Synthego has played a critical role in unlocking the potential of CRISPR, advancing its ease of adoption and democratizing genome engineering. Starting as a provider of CRISPR reagents, Synthego has rapidly evolved into one of the world’s leading authorities on CRISPR. The company’s full stack genome engineering platform accelerates research and enables scientists to study the fundamentals of biology, develop novel therapeutics for human disease, advance agriculture, and produce sustainable energy and chemicals.
"Synthego incorporates expertise in biology, automation, and computer science to push the boundaries of biotechnology. We’ve developed a fully automated platform, supported by next-generation informatics and machine learning algorithms, for the design, modeling, execution, and analysis of CRISPR projects," said Paul Dabrowski, Synthego CEO.
As the leading provider of genome engineering solutions, Synthego is uniquely qualified to partner with companies at the forefront of innovation across industries and serve as the platform for developing and advancing their CRISPR strategies.
"Our vision is to make precise, high-throughput genome engineering available to every scientist. By enabling rapid, consistent, and cost-effective research we expect to contribute to the development of promising new therapies for human disease and revolutionary advancements in multiple industries," said Michael Dabrowski, Synthego’s President.
Synthego’s automated synthesis and genome engineering platforms have led to the development of proprietary software that accurately predicts editing outcomes for any target sequence in multiple cell types and species. These advanced computational models allow researchers to rapidly design complicated genome modifications with a high degree of predictability and confidence, significantly reducing the time required to successfully edit the genome with the desired result.
Fast Company’s Most Innovative Companies issue recognizes pioneering companies across 36 categories, from biotech to artificial intelligence to wellness. More than three dozen Fast Company editors, reporters, and contributors surveyed thousands of companies to create these lists.
Read more about Synthego in Fast Company’s Most Innovative Companies issue at www.fastcompany.com/MIC.
Synthego is a leader in biotechnology, dedicated to delivering best-in-class CRISPR solutions alongside an expanding molecular and clinical diagnostics portfolio with a mission to accelerate research and development in the pursuit of improved human health. By providing unparalleled access to CRISPR solutions at scale, Synthego enables agility in life science discovery and clinical advancement. With streamlined licensing models, custom manufacturing capabilities and exceptional technical expertise, Synthego empowers researchers and therapeutic developers to unlock better patient outcomes by advancing discovery, diagnostics, and the next generation of advanced therapies.
Greg Huegerich
VP, Marketing
[email protected]
Cart
Account
Your Orders
Sign In